Bio-Rad Laboratories (BIO-B) Receivables - Net (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Receivables - Net data on file, last reported at $426.2 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $426.2 million, changed 0.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $426.2 million (changed 0.35% YoY), and the FY2025 annual result was $460.6 million, up 1.79% from the prior year.
• Receivables - Net slipped to $426.2 million in Q1 2026 per BIO-B's latest filing, from $460.6 million in the prior quarter.
• Over five years, Receivables - Net peaked at $498.3 million in Q1 2023 and troughed at $424.7 million in Q1 2025.
• A 5-year average of $460.5 million and a median of $460.6 million in 2025 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2022 and 2024: Receivables - Net gained 16.79% in 2022, then fell 10.73% in 2024.
• A 5-year view of Receivables - Net shows it stood at $494.6 million in 2022, then retreated by 1.14% to $489.0 million in 2023, then dropped by 7.46% to $452.5 million in 2024, then climbed by 1.79% to $460.6 million in 2025, then decreased by 7.47% to $426.2 million in 2026.
• Business Quant data shows BIO-B's Receivables - Net at $426.2 million in Q1 2026, $460.6 million in Q4 2025, and $464.7 million in Q3 2025.